2024
Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition
Rackear M, Quijano E, Ianniello Z, Colón-Ríos D, Krysztofiak A, Abdullah R, Liu Y, Rogers F, Ludwig D, Dwivedi R, Bleichert F, Glazer P. Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition. Oncotarget 2024, 15: 699-713. PMID: 39352803, PMCID: PMC11444335, DOI: 10.18632/oncotarget.28651.Peer-Reviewed Original ResearchConceptsTumor targetingMonoclonal antibody therapyTumor-specific targetingCell uptakeNucleic acid bindingCell surface antigensAntibody therapyHuman variantsClinical successCell-penetrating antibodiesAcid bindingSystemic administrationSurface antigensTumorRAD51 inhibitionAntibody platformMechanism of cell penetrationBind RAD51AntibodiesFull-lengthSpecific targetsCell penetrationDisease targetsCellsAutoantibodies
2008
Counselors’ Experiences Treating Methadone-maintained Patients with Chronic Pain: A Needs Assessment Study
Barry DT, Bernard MJ, Beitel M, Moore BA, Kerns RD, Schottenfeld RS. Counselors’ Experiences Treating Methadone-maintained Patients with Chronic Pain: A Needs Assessment Study. Journal Of Addiction Medicine 2008, 2: 108-111. PMID: 21768980, DOI: 10.1097/adm.0b013e31815ec240.Peer-Reviewed Original ResearchChronic painOpioid agonist treatment programPain management referralsMethadone-maintained patientsOverall caseloadMMT patientsOngoing painPain medicationPatient's painSuch patientsManagement referralsPsychologic componentsPainPatientsDrug useTreatment programSpecialized trainingNeeds assessment studyNeeds assessmentCaseloadAssessment studiesSpecific targetsMedicationsMethadoneReferral
1996
Oncology
DeVita V, Deisseroth A. Oncology. JAMA 1996, 275: 1833-1834. PMID: 8642736, DOI: 10.1001/jama.1996.03530470061036.Peer-Reviewed Original Research
1995
Mutagenesis of the COOH-terminal Region of Bacteriophage T4 regA Protein (∗)
O'Malley S, Sattar A, Williams K, Spicer E. Mutagenesis of the COOH-terminal Region of Bacteriophage T4 regA Protein (∗). Journal Of Biological Chemistry 1995, 270: 5107-5114. PMID: 7890619, DOI: 10.1074/jbc.270.10.5107.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceBacterial ProteinsBacteriophage T4Base SequenceBinding SitesChymotrypsinCircular DichroismCloning, MolecularDNA PrimersGenes, ViralKineticsMolecular Sequence DataMutagenesis, Site-DirectedPeptide FragmentsPoly UProtein ConformationRecombinant ProteinsSequence DeletionTranscription FactorsConceptsBacteriophage T4 regA proteinRegA proteinPhe-106Deletion mutantsWild-type regA proteinAmino acid substitutionsCOOH-terminal regionSpecific RNA ligandsT4 proteinsTranslational repressorRNA ligandsPartial proteolysisAcid substitutionsMutantsAmino acidsProteinRNAMajor siteNucleic acidsProteolysisOverall free energyChymotryptic cleavageSpecific targetsDomain structureAffinity
1987
Developmental therapeutics and the acquired immunodeficiency syndrome.
DeVita V, Broder S, Fauci A, Kovacs J, Chabner B. Developmental therapeutics and the acquired immunodeficiency syndrome. Annals Of Internal Medicine 1987, 106: 568-81. PMID: 2435201, DOI: 10.7326/0003-4819-106-4-568.Peer-Reviewed Original ResearchConceptsHuman T-lymphotropic virus type IIIPotential screening targetsTreatment of AIDST4 subsetOverwhelming infectionImmunodeficiency syndromeOpportunistic infectionsDevelopmental therapeuticsImmune competenceAntiviral drugsViral DNA polymeraseScreening targetsType IIIInfectionAIDSViral integrationDrugsSpecific targetsEncouraging resultsPatientsSyndromeLymphocytes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply